- Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress
- Transactions in Connection with Share Buy-back Program
- Genmab Announces Financial Results for the First Quarter of 2024
- TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
- Transactions in Connection with Share Buy-back Program Genmab
- Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2024
- Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
- Completion of share buy-back program
- Genmab Announces Initiation of Share Buy-Back Program
- Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
More ▼
Key statistics
On Friday, Genmab A/S (0MGB:LSE) closed at 2,029.25, 11.22% above the 52 week low of 1,824.50 set on Feb 13, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2,028.25 |
---|---|
High | 2,029.25 |
Low | 2,029.25 |
Bid | 1,993.00 |
Offer | 2,095.00 |
Previous close | 2,037.25 |
Average volume | 9.13k |
---|---|
Shares outstanding | 66.12m |
Free float | 66.12m |
P/E (TTM) | 24.03 |
Market cap | 131.58bn DKK |
EPS (TTM) | 82.80 DKK |
Data delayed at least 15 minutes, as of May 17 2024 15:44 BST.
More ▼